The Different Faces of Chronic Lymphocytic Leukemia - Two Clinical Cases
| Autor: | Doroteya K. Todorieva, Nikolai Tz. Tzvetkov, Vanya S. Popova, Ivailo G. Hristov, Kalina K. Ignatova, Lachezar H. Bogdanov, Pencho T. Tonchev, Dobromir D. Nguen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty business.industry Chronic lymphocytic leukemia Public health General Engineering Pharmacy medicine.disease Clinical pharmacy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine lymphocytic leukemia business secondary cancer low doses Ibrutinib |
| Popis: | Summary Chronic lymphocytic leukemia is one of the most common types of leukemia affecting adults over 65 years of age [1]. The disease is a part of the so-called indolent lymphomas and has a variable clinical course, defined by many factors. In recent years, knowing better the pathogenetic mechanisms of the disease, significant advances in the treatment have been made [2]. Monoclonal antibodies, immunomodulators, tyrosine kinase inhibitors, anti-apoptotic Bcl-2 protein inhibitors have been approved for clinical practice. Nevertheless, the development of tumor resistance and recurrence of the disease remains a challenge for hematologists, biologists, and pharmacists. We present two clinical cases of patients of both age groups (young adults and adults), in whom treatment was started with a Bruton’s tyrosine kinase (BTK) inhibitor, after inadequate response to immunochemotherapy (CIT). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|